News: Palatin Technologies, Inc. (NYSEMKT:PTN) belongs to Healthcare sector and Diagnostic Substances industry. Palatin Technologies, Inc. (NYSE MKT: PTN) announced that after the end of its permitting concurrence with AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) for elite North American rights to create and market Rekynda™ (bremelanotide), an investigational item intended for on-request treatment of hypoactive sexual yearning issue (HSDD) in pre-menopausal ladies, it will hold a telephone call and sound webcast to examine the authorizing understanding and next strides for Palatin. The permitting understanding is relied upon to shut in the principal quarter of timetable year 2017.
The call will talk about Palatin’s part in further improvement and administrative endorsement of Rekynda, and potential permitting exchanges outside North America. The call will likewise examine Palatin’s foreseen next strides in its other medication improvement programs, tallying its melanocortin receptor-1 agonist peptides for treatment of incendiary and dermatologic ailment signs, melanocortin receptor-4 agonist mixes for treatment of stoutness and diabetes, and natriuretic peptide receptor-A agonist mixes for treatment of cardiovascular and pneumonic signs.
Palatin will pronounce the date and time of its telephone call and sound webcast not long after shutting of the permitting concurrence with AMAG Pharmaceuticals.
Summary: Palatin Technologies, Inc. is a biopharmaceutical organization creating focused on, receptor-particular peptide therapeutics for the treatment of infections with noteworthyunmet restorative need and business potential. Palatin’s system is to create items and after that frame advertising coordinated efforts with industry pioneers keeping in mind the end goal to expand their business potential.